Objective. Azathioprine (AZA) metabolism largely parallels the endogenous purine pathways. To date, thiopurine methyltransferase (TPMT) deficiency has been reported as a cause of AZA-related bone marrow toxicity in 1 patient with rheumatoid arthritis (RA). We therefore studied purine enzyme activities in 3 patients with RA who experienced AZA-related bone marrow toxicity.
azathioprine (AZA) when it is taken in dosages com monly prescribed for the treatment of rheumatoid arthritis (RA) (<3 mg/kg/day). After conversion to 6-mercaptopurine, the metabolism of AZA parallels the endogenous purine pathways ( Figure 1 ). Low activity of thiopurine methyltransferase (TPMT) has occasionally been reported as a cause of AZA-related bone marrow toxicity in patients with a variety of conditions, including 1 with RA (1-3). However, other mechanisms must be present as well, since normal TPMT activity was found in 9 renal transplant patients with leukopenia attributed to AZA (4) . To date, no cases of AZA-related bone marrow toxicity associated with abnormalities in purine enzymes have been re ported in the rheumatology literature. We studied the activities of 3 key enzymes of purine catabolism in 3 patients with RA who experienced AZA-related bone marrow toxicity and in 16 control patients with RA.
PATIENTS AND METHODS
Control RA patients. Sixteen patients (9 male, 7 female) with RA (15 rheumatoid factor [RF] positive) with normal liver and kidney function, who had shown no bone marrow toxicity after at least 6 months of treatment with AZA (1-3 mg/kg day) served as the control group.
Patients. Three patients who experienced acute AZA-related bone marrow toxicity were studied. Patient 1, a 63-year-old man with RF-positive RA since 1973, had been treated with aurothioglucose 40 mg monthly for >10 years when AZA 2.0 mg/kg daily was added to his treatment regimen because of active polyarthritis with nodules and vasculitic cutaneous ulcers. Except for slight anemia, hema tologic parameters and kidney function were normal at that time. After 4 weeks, pancytopenia developed, and both AZA and aurothioglucose had to be discontinued (Table 1) (Table 1) . Platelet transfusions had to be given and prednisone (60 mg/day) was started, but the prednisone dosage could be tapered rapidly. After 3 weeks, only slight anemia remained (hemoglobin 6.1 mmoles/liter), and the WBC and platelet counts had returned to normal. Patient 3, a 57-year-old man with RF-positive RA since 1972, has recently been described elsewhere (6). Clin ical data are summarized in Table I .
Laboratory assessments. Lymphocyte activities of 5'-nucleotidase (5NT) and purine nucleoside phosphorylase (PNP) and erythrocyte activities of TPMT were measured according to methods described previously ( 
RESULTS
Blood sam ples for measurement of purine en zym e activities in the patients were obtained at least 3 months after hematologic abnormalities had resolved. N one o f the subjects studied had received blood transfusions within the 4 months prior to blood draw ing for purine enzym e measurement. All subjects had normal kidney and liver function test results and Our observations in patients 1 and 2 confirm the association of TPMT deficiency with AZA-related bone marrow toxicity. A ctivity o f 5NT measured in patient 3 was well below the low est value found in the RA patients who served as a control group. This condition may lead to increased levels o f thionucleo tides, causing increased susceptibility to bone marrow toxicity during treatment with AZA.
Two major forms o f 5NT are recognized: ecto-5NT and cytosolic 5NT (13). Ecto-5N T is located on outer membranes, which are not permeable for thio nucleotides, and most likely plays no role in the intracellular thiopurine metabolism and its subsequent cytotoxicity (14, 15) . This is supported by the observa tion that in vitro drug resistance to 6-thioguanine in childhood lym phoblastic leukemia is not related to ecto-5NT activity and is associated with high cytosolic 5NT activity (16). Our assay measured total 5NT activity. It seem s reasonable that low cytosolic 5NT would account for the low total 5NT activity levels we recently found to be associated with AZA-related bone marrow toxicity in 3 patients, including the 1 reported here and 2 renal transplant recipients (6). 5NT activity varies betw een lym phocyte subsets and with matura tion state. Although the use o f a control group o f patients with RA, all o f whom had taken A ZA , makes it less likely that such differences will have influenced our results, this possibility cannot be fully excluded.
In conclusion, deficiency of purine enzym es, in cluding TPMT and 5NT, may be a cause o f azathioprinerelated bone marrow toxicity. If low activity o f TPMT or 5NT is found in a patient who is believed to have AZA-related bone marrow toxicity, a rechallenge should be avoided, or, when inevitable, the drug should be started at a lower dosage and with close monitoring o f hem atologic parameters. In relatives o f a person who has experienced AZA-related bone marrow toxicity or one who has been shown to have a TPMT deficiency, determination o f TPMT activity before the start o f AZA treatment is suggested. Al though at present, measurement o f purine enzym es is laborious, it is conceivable that when m ethods becom e less expensive and more readily available, this poten tially life-threatening side effect o f AZA can be pre vented.
